|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 970 DKK | +0.26% |
|
-3.25% | +38.95% |
| 05:13pm | ETF of the week: Investing in strong trends with the momentum theme |  |
| 02:53pm | NOVO NORDISK : Deutsche Bank remains its Buy rating | ZD |
July 2 (Reuters) - The U.S. Food and Drug Administration said on Tuesday it had warned a website called ozempen.com on Tuesday against unlawfully selling versions of Novo Nordisk's weight-loss drugs.
The FDA said the website was offering unapproved versions of obesity and diabetes drugs Ozempic and Wegovy.
"These products are only available pursuant to a prescription from a licensed practitioner," the health regulator said. (Reporting by Christy Santhosh in Bengaluru; Editing by Maju Samuel)
| 1st Jan change | Capi. | |
|---|---|---|
| +38.95% | 621B | |
| +54.07% | 809B | |
| -7.05% | 351B | |
| +15.44% | 319B | |
| +5.72% | 289B | |
| +14.21% | 238B | |
| -0.45% | 221B | |
| +14.58% | 218B | |
| +7.42% | 166B | |
| -3.79% | 157B |
NOVO NORDISK A/S 
